Strong effector functions and high binding affinities, such as FcγR profiles, FcγRIIC-ORF, large numbers of FcγRIII and FcγRIIC gene copies, IgG3-G3m15/16, and non-lamellar glycosylated IgG variants [53], may be associated with “good” outcomes in the prevention of infectious diseases or antibody-mediated therapy. This evidence concerns the gene FCGR2A and infectious disease.